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Adoptive transfer experimental autoimmune encephalomyelitis (AT-EAE) is an inﬂammatory demyelination that recapitulates in mouse
spinal cord (SC) the human multiple sclerosis disease. We now analyze previously reported cDNA array data from age-matched young
female adult control and passively myelin antigen-sensitized EAE mice with regard to organizational principles of the SC transcriptome in
autoimmune demyelination. Although AT-EAE had a large impact on immune response genes, broader functional and chromosomal gene
cohorts were neither signiﬁcantly regulated nor showed signiﬁcant changes in expression coordination. However, overall transcriptional
control was increased in AT-EAE and the proportions of transcript abundances were perturbed within each cohort. Striking likenesses
and oppositions were identiﬁed in the coordination proﬁles of genes related to myelination, calcium signaling, and inﬂammatory response
in controls that were substantially altered in AT-EAE. We propose that up- or down-regulation of genes linked to those targeted by the
disease could potentially compensate for the pathological transcriptomic changes.
Keywords: autoimmune demyelination, calcium signaling, chemokines, cytokines, EAE, inﬂammatory response, multiple sclerosis,
myelination
INTRODUCTION
Experimental autoimmune encephalomyelitis (EAE), a well-established
animal model that recapitulates many clinical and pathophysiological
aspects of multiple sclerosis (MS, Baranzini et al., 2005) is a T-cell-
mediated inﬂammatory demyelinating disease of the central nervous
system (CNS). Like MS, EAE is physiologically characterized by disturbed
axonal conduction leading to motor and sensory impairment. Pathological
ﬁndings in both MS and EAE include inﬁltration of activated peripheral
inﬂammatory cells into the CNS, loss of myelin and oligodendrocytes,
edema, and axonal damage. Astrocytic hypertrophy and astrogliotic
scarring are also prominent features of both MS and EAE, and these
changes in astrocytes may contribute to conditions that lead to lasting
axonal damage, oligodendrocytic loss, and insufﬁcient or absent
remyelination. Adoptive transfer (AT-) EAE is induced by injecting myelin
antigen-sensitized T-cells obtained from previously immunized syngeneic
donor animals. Although more laborious, this form of EAE has a highly
synchronous onset and disease course (Mokhtarian et al., 1984; Pitt etal.,
2000). In AT-EAE, myelin basic protein reactive T-cells initiate an immune
attack against CNS myelin, characterized by cytokine production and cell
death.
There is a rich literature regarding gene expression changes both
during normal development and differentiation of myelinating cells (e.g.,
D’Antonio et al., 2006; Garbay et al., 1998; Gokhan et al., 2005; Jiang
et al., 2005) and also the changes that occur acutely (within a day),
delayed (within a week), and chronically (several weeks and longer
thereafter) following spinal cord (SC) injury (e.g., Carmel et al., 2001; Di
Giovanni et al., 2003, see also comprehensive overview in Bareyre and
Schwab, 2003). Genomic effects of SC injury have also been compared
with other conditions related to CNS demyelinating disease such as MS
(e.g., Lock et al., 2002; Lock and Heller, 2003) and mouse-EAE (e.g.,
Matejuk et al., 2003; Xu et al., 2003). Moreover, several studies have
shown altered expression of genes responsible for myelination in a variety
of CNS pathologies (e.g., Haroutunian et al., 2007; Kumar et al., 2006).
This report extends the analysis of our previously published cDNA
microarray study (Brand-Schieber et al., 2005) in which we compared the
transcriptomes of SC from female syngeneic, age-matched control and
AT-EAE SJL/J mice at the peak of clinical disability (clinical index
4 ¼ hind- andfront-limb paralysis). Thedisease was inducedbyinjecting
MBP-primed immune cells into syngeneic recipients. We reported that,
compared to healthy controls, SC of AT-EAE mice at the peak of disability
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10.3389/neuro.07.displayed axonal dystrophy, extensive inﬁltration of the lumbar ventral
white matter with CD11b-immunoreactive monocytes, and a threefold
decrease in mRNA encoding the gap junction protein connexin43 (Gja1,
connexin43, Cx43).
A subset of 3776 distinct genes with known protein products whose
expression levels were adequately quantiﬁed in all arrays and averaged
for all quantiﬁable spots probing the same gene, was selected for
further analysis reported in this paper. In order to test the hypothesis
that coordinated expression with Cx43 might account for some of the
observed altered patterns of gene expression, we have compared the
coordination proﬁle of Gja1 to those of the immune response and
myelination genes.
MATERIALS AND METHODS
Data set
Brieﬂy, 60 mg total RNA, extracted in trizol from each set of two SC of
control (C) and AT-EAE (E) mice was reverse transcribed into cDNA using
ﬂuorescent dUTPs [Cy3-dUTP (green, g) or Cy5-dUTP (red, r)]. The labeled
cDNAs were hybridized overnight at 508C with four 27 k cDNA
microarrays produced by the Microarray Facility of the Albert Einstein
College of Medicine (http://129.98.70.229) in the combinations:
C1(r)C2(g), C3(r)C4(g), E1(r)E2(g), E3(r)E4(g) (‘‘multiple yellow’’ strategy,
see Iacobas et al., 2006a). The images were acquired and primarily
analyzed with GenePix
TM Pro 4.1 software (www.axon.com) then
normalized according to our in-house developed algorithm. The input
data for subsequent analyses were the ratios between the normalized net
red/green ﬂuorescence of that spot and the average total net red/green
ﬂuorescence of all valid spots in the slide.
The microarray study was performed according to the standards of the
MicroarrayGeneExpressionDataSociety(MGED)anddatacomplyingwith
the ‘‘Minimum Information About Microarray Experiments’’ (MIAME,
Brazma et al., 2001) have been deposited in the National Center for
Biotechnology Information Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo) as series GSE2446.
Detection of signiﬁcant regulation
We considered a gene as signiﬁcantly regulated in AT-EAE SC compared
to control if the absolute fold change >1.5  and the p-value of the
heteroscedastic t-test (two-sample unequal variance) applied to the
means of the background subtracted normalized ﬂuorescence values in
the four biological replicas of the compared transcriptomes was <0.05.
Followingpreviouslypublishedprocedures(Iacobasetal.,2007a; Iacobas
et al., 2007b), we have also tested whether large groups of genes sharing
same chromosomal location or encoding functionally similar proteins
(hereafter termed cohorts) exhibit speciﬁc interactions that might regulate
and/or perturb the cohort expression proﬁle. Thus, a gene cohort was
considered as signiﬁcantly regulated if the average expression level of the
composing genes was changed by factor larger than 1.5 and the p-value
with the Bonferroni adjustment applied to multiple comparisons (Draghici,
2003; Iacobas et al., 2005a; Stekel, 2003) was less than 0.05. The
expression of a gene cohort was considered as signiﬁcantly perturbed if
the standard deviation ofthe fold changes within that groupexceeded 1.5.
Figure 1. Expression regulation of gene cohorts in AT-EAE mouse spinal cord. A–B. Log2ratios (negative for down-regulation) and standard deviation of
expression ratios of gene cohorts sharing the samemolecular function (A)or chromosomal location (B).Note that while the average fold change was less than1.5
for all cohorts, the standard deviation of the fold change exceeded 1.5. Highest standard deviations were obtained for JAE genes and for those located on
chromosome 17. (C) Heatmap of the regulated JAE-J genes. C1–C4 ¼ logratios in the four controls, E1–E4 ¼ logratios in the four AT-EAE mice. All logratios
were computed with respect to the average expression level in control mice. Red/green/black color indicates up/down/no regulation in the respective set. Note
both the reproducibility (green, red, or black color for all four sets of the same condition) and the variability (non-uniform nuance of the color) of the gene
expression patterns among the animals of the same condition.
Iacobas et al.
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transcript abundances within the cohort were considerably altered,
thereby potentially introducing ‘‘bottlenecks’’ in pathway dynamics by
perturbed transcriptomic ‘‘stoichiometry’’ (Iacobas et al., 2007a; Iacobas
et al., 2007b) which may also change the probability distribution of their
outcomes. As in previous papers (Iacobas et al., 2005a; Iacobas et al.,
2007a; Iacobas et al., 2007b), the genes were again classiﬁed in the
following functional cohorts: CSD,Cellcycle, shape, differentiation, death;
CYT, cytoskeleton; ENE, energy metabolism; JAE, cell junction, adhesion,
extracellular matrix; RNA, RNA processing; SIG, cell signaling; TIC,
Table 1. Regulation of immune response genes in AT-EAE spinal cord.
Name Symbol X p
Histocompatibility 2, class II antigen A, alpha H2-Aa 26.37 0.000
Complement component 1, q subcomponent, alpha polypeptide C1qa 10.03 0.000
Guanylate nucleotide-binding protein 2 Gbp2 9.10 0.000
Complement component 1, q subcomponent, beta polypeptide C1qb 8.45 0.000
Proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2) Psmb9 8.33 0.000
Histocompatibility 2, class II antigen A, beta 1 H2-Ab1 6.67 0.000
Histocompatibility 2, L region H2-L 6.50 0.000
Histocompatibility 2, K region H2-K 6.33 0.000
Macrophage expressed gene 1 Mpeg1 6.08 0.000
Fc receptor, IgG, low afﬁnity III Fcgr3 5.52 0.001
Histocompatibility 2, D region locus 1 H2-D1 5.30 0.001
Chemokine (C–C motif) ligand 9 Ccl9 5.26 0.001
Interferon-induced transmembrane protein 3 Iﬁtm3 4.46 0.001
B lymphoma Mo-MLV insertion region 1 Bmi1 4.37 0.001
Complement component 3 C3 4.33 0.005
Interferon-induced transmembrane protein 1 Iﬁtm1 4.23 0.000
Histocompatibility 2, class II, locus DMa H2-DMa 4.22 0.001
Interleukin 2 receptor, gamma chain Il2rg 3.55 0.007
Tumor necrosis factor, alpha-induced protein 2 Tnfaip2 3.53 0.000
T-cell receptor alpha, variable 22.1 Tcra-V22.1 3.51 0.000
CD44 antigen Cd44 3.24 0.000
Proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional protease 7) Psmb8 3.24 0.001
LPS-responsive beige-like anchor Lrba 3.22 0.002
SAM domain and HD domain, 1 Samhd1 3.04 0.000
Interferon regulatory factor 1 Irf1 3.04 0.000
Interleukin 7 receptor Il7r 3.03 0.001
Interferon consensus sequence-binding protein 1 Icsbp1 3.01 0.000
B-cell leukemia/lymphoma 2-related protein A1d Bcl2a1d 2.99 0.000
Complement component factor h Cfh 2.91 0.002
Interleukin 1 family, member 6 Il1f6 2.83 0.003
Interferon activated gene 203 Iﬁ203 2.79 0.001
20-50-Oligoadenylate synthetase-like 2 Oasl2 2.71 0.006
SLAM family member 8 Slamf8 2.66 0.000
Fc receptor, IgE, high afﬁnity I, gamma polypeptide Fcer1g 2.63 0.005
Immunoglobulin superfamily, member 7 Igsf7 2.61 0.004
Interferon-induced transmembrane protein 3-like Iﬁtm3l 2.56 0.000
Immediate early response 3 Ier3 2.55 0.027
Chemokine (C–C motif) ligand 22 Ccl22 2.46 0.012
Histocompatibility 2, Q region locus 7 H2-Q7 2.44 0.004
Histocompatibility 2, complement component factor B H2-Bf 2.44 0.000
Small chemokine (C–C motif) ligand 11 Ccl11 2.41 0.000
IL2-inducible T-cell kinase Itk 2.39 0.000
Histocompatibility 13 H13 2.38 0.024
Interferon regulatory factor 6 Irf6 2.30 0.001
Proteasome (prosome, macropain) 28 subunit, alpha Psme1 2.27 0.003
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Cd47 2.22 0.000
Chemokine-like factor super family 3 Cklfsf3 2.17 0.002
Interleukin 11 receptor, alpha chain 1 Il11ra1 2.17 0.000
ICOS ligand Icosl 2.07 0.000
T-complex-associated testis expressed 3 Tcte3 2.07 0.000
CD1d1 antigen Cd1d1 2.01 0.001
Chemokine (C motif) ligand 1 Xcl1 2.00 0.006
Histocompatibility 2, class II antigen E beta H2-Eb1 1.78 0.042
Ia-associated invariant chain Ii 1.76 0.023
Immunoglobulin superfamily, member 8 Igsf8  2.20 0.000
Integrin alpha FG-GAP repeat containing 1 Itfg1  2.28 0.000
X, expression ratio (negative for down-regulation) in AT-EAE with respect to control; p, p-value.
Transcriptomic network alteration in AT-EAE
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function not yet assigned.
Variability of transcript abundance and TRA control
The relative estimated (TRA) variability (REV) and the gene expression
stability(GES)ofbothcontrolandexperimentalspecimenswerecomputed
as previously described (Iacobas et al., 2003). Since basic transcriptional
mechanisms are expected to be similar in a homogeneous set of mice,
whereas the local conditions may differ from mouse to mouse, lower REV
values are interpreted as indicating lower sensitivity to the local
conditions, most probably resulting from increased TRA control, while
higher REV values indicate reduced TRA control. Therefore, GES scores
reveal the priorities of control over the transcript abundance, with
GES ¼ 100 indicating the most stably expressed gene (highest priority in
transcript abundance control) and GES ¼ (100/number of quantiﬁed
genes) the least controlled gene. We organized a database containing the
REV and GES values in both conditions and identiﬁed the genes for which
the system preserved or signiﬁcantly changed the priorities of TRA control
in AT-EAE mice. Both analyses of expression variability and TRA control
were extended to the cohorts of genes to test whether the average
variability of the cohort was signiﬁcantly changed in AT-EAE, and whether
patterns of hierarchy in expression control among cohorts (signiﬁcantly
different average GES values) were altered in AT-EAE.
TRA coordination
In order to gain insight into whether expression of individual genes is
linked to each other so that the protein amounts would respect the
‘‘stoichiometry’’ of the biochemical reactions, we performed analysis of
TRA coordination using the pair-wise Pearson correlation coefﬁcient
between sets of expression levels in biological replicas (procedure in
Iacobas et al., 2005a) of both individual genes and gene cohorts to detect
speciﬁc interactions that may be responsible for perturbation of functional
pathways induced by the AT-EAE. At 5% statistical signiﬁcance, two
genes were considered as synergistically expressed if the Pearson
correlationcoefﬁcientrij>0:9,antagonisticallyexpressed ifrij> 0:9,
and independently expressed if jrijj>0:05. For each gene, we
determined the synergome, antagome, and exclusome (i.e., sets of
synergistically, antagonistically, or independently expressed partners of a
given gene), as well as the coordination proﬁle (i.e., the set of the
correlation coefﬁcients between expression levels of that gene and each
other gene in the biological replicas). Together, the synergome and the
antagome of a gene forms its expressome. From the point of view that
genes whose protein products work together in functional pathways
should be coordinately expressed (Iacobas et al., 2007b), the expressome
of agene indicates the extent ofthe transcriptomic network related tothat
gene, while its exclusome indicates the delimitations of this network with
respect to other networks. Finally, we compared the coordination proﬁles
of selected genes by computing their overlap (OVL), an indicator ranging
from  100 to 100% (Iacobas et al., 2007b), with high positive values
indicating likeness, high negative values opposition, and values close to
zero indicating neutrality of the coordination proﬁles. We termed the gene
pairs with OVL > 80 or OVL <  80 as ‘‘see-saw’’ partners (Iacobas
et al., 2007a).
RESULTS
Expression regulation
As previously reported (Brand-Schieber et al., 2005), we found 1433
regulated genes, encompassing all functional classes and located on all
chromosomes, thereby indicating a high degree of complexity of the
transcriptomic alterations induced by AT-EAE. Affected pathways were
identiﬁed using GenMapp and MappFinder database searches (www.
genemapp.org; Dahlquist et al., 2002; Doniger et al., 2003). High up-
regulated genes were associated with immune and defense response,
moderate up-regulated genes were associated with the proinﬂammatory
response, antigen presentation and processing, immune cell migration,
and endosome transport. Low (but still signiﬁcant) up-regulation included
genes related to cholesterol metabolism and cytokine biosynthesis. As
antigen presentation and cytokine biosynthesis are components of the
Table 2. Representative examples of signiﬁcantly regulated JAE genes in EAE spinal cord (EAE) and in Cx43 null brain (BR).
GB ACC Name Symbol EAE BR
AA266651 Afamin Afm 3.29 1.64
AW552701 Amyloid beta (A4) precursor protein App  3.00  5.47
AA544881 Attractin Atrn 1.65 1.53
AU044759 Cadherin 22 Cdh22 2.51 1.68
AW537209 Calsyntenin 1 Clstn1  2.26  2.24
AI573427 Catenin beta Catnb  2.26  2.79
AA154812 Claudin 10 Cldn10 1.96 1.59
AI425965 Contactin 1 Cntn1  1.87  1.77
AU040950 Ependymin 2 Epdm2-pending  4.13  1.69
W58845 Fc receptor, IgE, high afﬁnity I, gamma polypeptide Fcer1g 2.63 1.52
AA277329 Histocompatibility 2, class II antigen E beta H2-Eb1 1.78 1.50
AA061908 Integrin alpha M Itgam 3.52 1.59
AW545236 Mitochondrial ribosomal protein L28 Mrpl28  1.72  1.92
C79334 Musculin Msc 2.01 1.64
AW537800 N-ethylmaleimide sensitive fusion protein attachment protein alpha Napa  4.17  1.82
AI323974 Neuropilin Nrp 1.77 1.64
C85793 Putative neuronal cell adhesion molecule Punc 1.90 1.60
AI414315 Rhomboid, veinlet-like 4 (Drosophila) Rhbdl4 1.51 1.59
AI327207 Tenascin C Tnc 2.52 1.78
AA249976 Xeroderma pigmentosum, complementation group C Xpc 1.64 1.58
Values in right-most columns indicate fold change (negative for down-regulation). Note that although fold changes differ, all listed genes were regulated
in the same direction in both experimental groups.
Iacobas et al.
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up-regulated to a major extent in EAE. Most prominently down-regulated
GO categories included heterochromatin, acid phosphatase, cytoplasm
organization and biogenesis, mitochondrial inner membrane presequence
translocase, regulation of coagulation and chemokine, and cytokine-
mediated signaling (zinc ﬁnger CCCH-type containing 15, Zc3h15 and
suppressor of cytokine signaling 5, Socs5).
We found that no single cohort of genes (open bars in Figures 1A and
1B) with regard to chromosomal location or function of the encoded
protein was entirely regulated unidirectionally, up- and down-regulations
of individual genes being roughly balanced within each cohort. An
example is shown in Figure 1C for part of the subcategory JAE. However,
this balance did not extend to the subcohorts: for example, the expression
levels of 54 of 56 signiﬁcantly regulated genes (96%) related to immune
response (part of the JAE cohort, see Table 1) showed signiﬁcant
increases, with histocompatibility 2 class II antigen A alpha (H2-Aa)
exhibiting the highest fold change (26.4 ).
Similarity of the regulomes of AT-EAE SC and Cx43 null brain
Since Cx43 was down-regulated in AT-EAE SC by about threefold, we
checked whether this alteration of Cx43 expression had similar effects on
other genes as observed in Cx43 null brain (Iacobas et al., 2005a), where
signiﬁcantly regulated genes were also located on all chromosomes and
encoded proteins of all major functional categories, extending beyond
those that might be expected to depend on junctional communication.
Indeed, we found substantial OVL between the regulomes of AT-EAE SC
and that of Cx43 null brain with respect to their controls (part of which are
listed in Table 2), with 84% of the 585 signiﬁcantly altered genes in both
samples exhibiting the same type of regulation.
Regulation of expression variability
Figure 1C illustrates the variability of gene expression among animals of
the same condition (note the non-uniform color nuances in the heatmap
representation). We found that the overall TRA variability increased from
42.5% in the control mice to 49.7% in the AT-EAE mice, indicating a
signiﬁcant (p < 0.0001) loss of the overall TRA control in the diseased
mice. This observation of overall increased variability in EAE mice
compared to controls was robust for all functional cohorts (Figure 2A) and
all chromosomal locations (Figure 2B) with a slight bias toward CYT
genes, perhaps reﬂecting the ongoing alterations in the tissue of these
animals. However, both control and EAE specimens had uniform control
stringencies among functional categories (Figure 2C) and chromosomal
locations (not shown) as indicated by the roughly uniform distributions of
the GES scores.
Table 3 presents examples of very stably and very unstably expressed
genes in the control mice that signiﬁcantly preserved or changed their
stability classes in AT-EAE mice.
TRA coordination
The average gene in control SC was found to be synergistically expressed
with 467 genes (i.e., 12.4% of 3776), antagonistically expressed with 401
(10.6 %), and independently expressed with 231 (6.1%). As illustrated in
Figure 3A, these numbers were not signiﬁcantly altered in the AT-EAE
mice: average synergome size ¼ 436 (11.5%), antagome ¼ 397
(10.6%), and exclusome ¼ 241 (6.4%). However, the networks of genes
that were connected to one another were markedly altered, as indicated
by the lack of correlation between the control and AT-EAE expressomes
and exclusomes. In both conditions, we found remarkably bimodal
distributions of coordination frequencies (Figure 3B).
Some genes exhibited very low numbers of coordinated partners as
compared to the average gene; for example, T-complex-associated testis
expressed 3 (Tcte3) and P2rx3 have expressomes covering only 2.4 and
2.5% of the sampled transcriptome. In contrast, other genes had large
numbers of coordinated partners, such as Spastin (Spast) with an
expressome of 45.3% of the transcriptome, and ATP synthase H
þ
transporting mitochondrial F1 complex gamma polypeptide 1 (Atp5c1),
whose expressome encompassed 45.2% of the transcriptome. A large
diversity of coordination degrees was found among the genes involved in
Figure 2. Regulation of the mean relative expression variability (REV) of
gene cohorts sharing the same molecular function (A) or chromosomal
location (B) in spinal cords of AT-EAE mice compared to control mice. (C)
Average gene expression stability (GES) of functional gene cohorts. Note the
uniformity of the two REV distributions both among functional classes:
REV(C) ¼ (42.9   2.3)%, REV(E) ¼ (50.2   2.3)% and among chromo-
somes: REV(C) ¼ (42.5   2.1)%, REV(E) ¼ (49.7   2.3)% and that all
functional and chromosomal cohorts became less stably expressed (higher
REV) in AT-EAE mice, with the highest increments in the transport into cell
(23.8%) and chromosome 13 (34.1%). Cytoskeleton genes were the most
unstably expressed in both conditions. Observe the quasi-uniform distribution
of GES values among functional categories for both control and AT-EAE
specimens.
Transcriptomic network alteration in AT-EAE
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instability in AT-EAE spinal cord with respect to controls.
STAB Name Symbol CHR FUNC GES-C GES-E REG
SS Phosphofructokinase, platelet Pfkp 13 ENE 98.04 98.17 #
SS Burkitt lymphoma receptor 1 Blr1 9 SIG 98.62 98.78 "
SS Ethanol induced 2 Etohi2 15 UNK 96.13 95.74 #
SS Cadherin 2 Cdh2 18 JAE 99.21 98.57 #
SS Ephrin A5 Efna5 17 JAE 97.38 98.04 #
SS START domain containing 7 Stard7 2 UNK 95.23 94.17 #
SS Bmi1 upstream gene Bup 2 UNK 96.64 98.07
SS Gene trap locus 3 Gtl3 8 TRA 98.44 99.92 #
SS Muscleblind-like 3 (Drosophila) Mbnl3 X CSD 96.72 98.25 #
SS Coatomer protein complex, subunit epsilon Cope 8 TWC 95.47 97.25
SS Translation factor sui1 homolog Gc20-pending 9 RNA 99.31 97.35 #
SS DiGeorge syndrome critical region gene 2 Dgcr2 16 TWC 96.61 98.81
SS Ribosomal protein L13 Rpl13 8 RNA 95.66 99.13 #
SS High mobility group box 1 Hmgb1 5 TRA 97.19 93.59 #
SS ADP-ribosylation factor-like 4 Arl4 12 SIG 98.23 94.44 "
SU Ornithine aminotransferase Oat 7 ENE 96.40 8.85
SU UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 4
Galnt4 10 ENE 88.29 0.45
SU Histone cell cycle regulation defective interacting protein 5 Hirip5 6 UNK 93.19 5.11 #
SU Chloride intracellular channel 1 Clic1 17 TIC 99.87 11.10
SU Interleukin-1 receptor-associated kinase 1 Irak1 X SIG 88.90 0.05
SU Tubulin, alpha 2 Tuba2 15 CYT 97.83 8.92
SU RE1-silencing transcription factor Rest 5 TRA 90.84 1.72
SU Acetyl-coenzyme A acyltransferase 1 Acaa1 9 ENE 99.97 10.70
SU Src homology 2 domain-containing transforming protein D Shd 17 SIG 95.60 6.04
SU T-complex-associated testis expressed 1 Tcte1 17 TWC 90.86 1.22
SU Coatomer protein complex, subunit zeta 1 Copz1 15 TWC 95.42 5.75
SU Sorting nexin 4 Snx4 16 TWC 94.65 4.69
SU Cleavage and polyadenylation speciﬁcity factor 1 Cpsf1 15 RNA 95.21 4.10
SU Cystathionase (cystathionine gamma-lyase) Cth 3 ENE 92.24 0.95
SU Chronic myelogenous leukemia tumor antigen 66 Cml66-pending 15 JAE 94.33 2.97
US RPEL repeat containing 1 Rpel1 13 UNK 0.69 99.76
US F-box and WD-40 domain protein 5 Fbxw5 2 UNK 1.69 99.47
US Ankyrin repeat domain 10 Ankrd10 8 TRA 4.42 98.28 "
US Chromobox homolog 3 (Drosophila HP1 gamma) Cbx3 6 TRA 3.68 96.03
US DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 Ddx24 12 TRA 4.40 96.00
US Protein phosphatase 2 (formerly 2A), regulatory
subunit B (PR 52), alpha isoform
Ppp2r2a 14 SIG 2.49 95.37
US Myotubularin-related protein 1 Mtmr1 X CYT 1.03 95.26
US GNAS (guanine nucleotide-binding protein, alpha
stimulating) complex locus
Gnas 2 SIG 3.20 94.84
US Coatomer protein complex, subunit gamma 2, antisense 2 Copg2as2 6 TWC 1.06 92.43
US Four jointed box 1 (Drosophila) Fjx1 2 UNK 2.15 92.03
US Glycogen synthase kinase 3 beta Gsk3b 16 SIG 4.05 91.68
US BH3 interacting domain death agonist Bid 6 CSD 1.38 91.42
US Solute carrier family 14 (urea transprorter), member 1 Slc14a1 18 TIC 0.56 91.39
US Eukaryotic translation initiation factor 2 alpha kinase 4 Eif2ak4 2 RNA 3.26 90.84
US Cytochrome b-561 Cyb561 11 ENE 2.99 90.23
UU Nectin-lke 1 Necl1-pending 1 UNK 0.21 6.94
UU Neural precursor cell expressed, developmentally
down-regulated gene 4
Nedd4 9 ENE 4.98 6.73
UU Brain protein 17 Brp17 1 UNK 4.82 6.62
UU MAD homolog 1 (Drosophila) Madh1 8 SIG 2.89 5.61
UU Myeloid/lymphoid or mixed-lineage leukemia 5 Mll5 5 TRA 0.13 4.93
UU Estrogen receptor 1 (alpha) Esr1 10 SIG 1.54 4.56
UU Mpv17 transgene, kidney disease mutant Mpv17 5 ENE 1.80 4.50
UU Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) B3Gat3 19 ENE 4.29 2.60
UU Ring ﬁnger protein 103 Rnf103 6 TRA 3.10 2.38
UU Metastasis suppressor 1 Mtss1 15 CYT 3.15 1.67
UU Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 Spock1 13 JAE 3.73 1.01
UU A disintegrin and metalloproteinase domain 19 (meltrin beta) Adam19 11 JAE 2.07 0.72
UU Guanine nucleotide-binding protein, alpha 11 Gna11 10 SIG 1.19 0.69
UU Transducin-like enhancer of split 4, E(spl) homolog (Drosophila) Tle4 19 TRA 0.90 0.64
UU Seri drox m l transferas mitochon Shmt2 10 ENE 0.29 0.37
CHR, chromosome location; FUNC, functional class; GES-C and GES-E are the gene expression stabilities in control C and AT-EAE (E) spinal cord while
arrows in the REG column indicate whether the gene was signiﬁcantly up- or down-regulated in E specimens.
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the selection, while Nsmaf was coordinated with only 5% of the selection
(Figure 3C).
Although coordination of the average gene was notsigniﬁcantlychanged
in AT-EAE mice, the coordinations within gene cohorts were markedly
affected. Thus, the coordination of 13 out of 16 quantiﬁed genes
related to myelination decreased signiﬁcantly, while the coordination
of stearoyl-coenzyme A desaturases 1 and 2 (Scd1, Scd2) and
sphingomyelin phosphodiesterase 1, acid lysosomal (Smpd1) increased
signiﬁcantly.
When the average coordination degree was computed for gene
cohorts, we found rather uniform distributions with regard to chromo-
somal location and functional categories in control as well as in AT-EAE
samples (Figures 4A–4D), similar to our ﬁndings in brain of the nenatal
mouse (Iacobas et al., 2007a). If both coordination and variability of gene
expression reﬂect control mechanisms to promote transcriptome stability,
we might expect that these parameters would be mathematically related.
Indeed, we found that the coordination decreased exponentially with the
expressioncontrol(GES),arobustobservationforbothconditions(Figures
4E and 4F).
Table 4 presents the genes with the largest and the smallest syner-
gomes, antagomes, and exclusomes in control SC and the corresponding
values in AT-EAE mice, while Table 5 presents the sizes of the syner-
gomes, antagomes, and exclusomes of the quantiﬁed immune response
genes in controls.
Table 6 presents examples of genes that preserved or signiﬁcantly
changed the expressome size in AT-EAE SC. Thus, the B-cell receptor-
associated protein 31 (Bcap31), that is preferentially associated with the
Figure3.Transcriptioncoordination.(A)The95%conﬁdenceintervalsofthepercentagesofsynergistically(Syn),antagonistically(Ant),andindependently(Ind)
expressed gene pairs in spinal cord of control (C) and AT-EAE (E) mice. Note that the intervals remained practically unchanged in AT-EAE. (B) Histograms of the
expression coordinations (SYN þ ANT) in control and AT-EAE spinal cord. Note the two modal distributions in both conditions, with two distinct groups of genes:
one group in which most genes are coordinately expressed with 4–8% of the other genes and the second group in which most genes are coordinately expressed
with40–44%oftheothergenes.(C)Examplesinwhichpercentagesofstatisticallysigniﬁcantcoordinationpartnersofmyelinationgenesdifferedbetweencontrol
and AT-EAE spinal cords. Chk, choline kinase; Fyn, Fyn proto-oncogene; Hmgcr, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; Mal, myelin and lymphocyte
protein T-cell differentiation protein; Mpz, myelin protein zero; Nsmaf, neutral sphingomyelinase activation-associated factor; Pdgfra, platelet derived growth
factor receptor alpha polypeptide; Pdgfrb, platelet derived growth factor receptor beta polypeptide; Pdgfrl, platelet-derived growth factor receptor-like; Plp,
proteolipid protein; Pmp22, peripheral myelin protein; Qk, quaking; Scd1, stearoyl-coenzyme A desaturase 1; Scd2, stearoyl-coenzyme A desaturase 2; Smpd1,
sphingomyelin phosphodiesterase 1 acid lysosomal; Smpdl3a, sphingomyelin phosphodiesterase acid-like 3A.
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coordination degree in both conditions, whereas other genes showed
substantial alterations in coordinated expression.
Transcriptomic ‘‘see-saws’’
We compared the coordination proﬁles of selected genes involved in
immune response, myelination, and calcium signaling by computing their
OVL. The rationale for selecting these genes was that EAE is a rodent
immune-cell-mediated inﬂammatory demyelinating disease and that
calcium signaling (Iacobas et al., 2006b) is directly related to myelination
(Butt, 2006; Fields, 2006). Although as expected, the coordination see-
saws were exceptions, as most gene pairs exhibited neutral coordination
proﬁles; in all functional categories, we identiﬁed genes with striking
likeness or opposition, as illustrated for Pmp22 in Figure 5 in controls.
Figure 5 illustrates also how the ‘‘see-saw’’ partnership (here of Pmp22)
in control SC was altered by disease.
Table 7 lists the most strikingly similar or opposite see-saw partners
within genes responsible for myelination, calcium signaling, and immune
response. The pair H2-DMa: Psmb9 (histocompatibility 2, class II, locus
DMa: proteosome (prosome, macropain) subunit, beta type 9 (large
multifunctional protease 2)) has the highest likeness, while the pair
Scd2:Plcl2 (stearoyl-coenzyme A desaturase 2: phospholipase C-like 2)
has the highest opposition as coordination proﬁles. Pmp22 shared with
Pdgfra956ofits1039synergisticpartners and561 ofits593antagonistic
partners, and with Itpr1 929 synergistic and 522 antagonistic partners. In
addition,667synergisticpartnersofPmp22areantagonisticforPdgfrland
979 are antagonistic for Grinl1a, while 442 antagonistic partners of
Pmp22 are synergistic for Pdgfrl and 557 are synergistic for Grinl1a. The
values ofthe OVL in legendof Figure5conﬁrmedthe higher similarity and
opposition of the coordination proﬁles of the illustrated genes.
DISCUSSION
Conﬁrmation of array data
Our microarray data are in surprisingly high qualitative agreement with
those previously obtained by another group on SC of spontaneous EAE
Figure 4. Average percentages of synergistically (Syn), antagonistically (Ant), and independently (Ind) expressed gene pairs in functional categories
(A and B), chromosomes (C and D) and GES percentiles for control (A, C, E) and AT-EAE (B, D, F) spinal cords. Note the quasi-uniform distributions of the
percentages in functional categories and chromosomal locations in both conditions, the not-signiﬁcant alteration of the percentages in AT-EAE mice and the
inverse exponential relationship between synergistic and antagonistic coordination and expression stability (GES percentile).
Iacobas et al.
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partners within the control (C) spinal cord and the corresponding values for AT-EAE (E) mice.
Type Name Symbol CHR FUNC SYN-C ANT-C IND-C SYN-E ANT-E IND-E
H-SYN A disintegrin and metalloprotease domain 10 Adam10 9 JAE 28.02 16.76 3.18 16.79 16.55 4.53
H-SYN Hermansky–Pudlak syndrome 1 homolog (human) Hps1 19 TWC 27.97 16.87 3.31 18.99 18.64 4.10
H-SYN Myotubularin-related protein 1 Mtmr1 X CYT 27.97 17.19 3.39 5.46 1.48 8.10
H-SYN Potassium channel tetramerisation domain containing 2 Kctd2 11 TIC 27.97 17.08 3.50 8.05 4.18 5.88
H-SYN Bromodomain containing 3 Brd3 2 TRA 27.94 16.66 3.39 4.77 2.01 14.14
H-SYN Carbamoyl-phosphate synthetase 2, aspartate
transcarbamylase, and dihydroorotase
Cad-pendin 5 ENE 27.94 16.98 3.39 17.51 18.30 3.84
H-SYN CBF1 interacting corepressor Cir-pending 2 TRA 27.94 16.90 3.44 14.30 10.99 4.69
H-SYN Enoyl-coenzyme A hydratase, short chain,
1, mitochondrial
Echs1 7 ENE 27.94 16.74 3.20 23.28 15.04 4.08
H-SYN Nuclear receptor subfamily 3, group C, member 1 Nr3c1 18 CSD 27.94 16.60 3.26 23.54 16.53 4.10
H-SYN Nuclear receptor coactivator 1 Ncoa1 12 CSD 27.91 17.16 3.42 8.08 4.90 4.74
L-SYN Glucose phosphate isomerase 1 Gpi1 7 ENE 0.85 2.38 21.82 4.40 1.43 16.37
L-SYN Exostoses (multiple)-like 3 Extl3 14 CSD 0.87 2.01 16.82 14.88 23.17 4.05
L-SYN Phosphoglycerate dehydrogenase like 1 Phgdhl1 14 ENE 0.87 2.75 15.89 5.99 10.51 5.16
L-SYN Cytotoxic T lymphocyte-associated protein 2 beta Ctla2b 12 JAE 0.90 1.67 25.85 19.12 14.22 3.55
L-SYN HLA-B-associated transcript 8 Bat8 17 TRA 0.90 2.38 21.64 17.51 13.06 3.60
L-SYN Nuclear factor of kappa light chain gene enhancer
in B-cells inhibitor, alpha
Nfkbia 12 TRA 0.90 1.69 25.50 12.39 15.39 4.37
L-SYN Phospholipase D3 Pld3 7 SIG 0.93 2.91 16.18 15.84 16.45 4.74
L-SYN Acetyl-coenzyme A acetyltransferase 1 Acat1 9 ENE 0.95 2.75 12.24 20.10 17.45 3.84
L-SYN Fucosidase, alpha-L-1, tissue Fuca 4 ENE 0.95 1.88 13.45 18.96 10.30 4.45
L-SYN Glyoxalase 1 Glo1 17 ENE 0.95 2.78 11.81 12.98 21.66 4.16
H-ANT Spastic paraplegia 7 homolog (human) Spg7 8 UNK 17.27 28.05 3.50 14.80 23.09 4.00
H-ANT Protein tyrosine phosphatase, non-receptor type 9 Ptpn9 9 SIG 17.13 28.02 3.42 1.14 3.87 16.58
H-ANT Dehydrogenase/reductase (SDR family) member 1 Dhrs1 14 ENE 16.95 27.99 3.58 3.95 8.58 6.09
H-ANT Kinesin family member 23 Kif23 9 TWC 16.84 27.97 3.31 16.63 17.32 4.18
H-ANT RNA and export factor-binding protein 2 Refbp2 1 TRA 16.92 27.97 3.34 16.74 22.70 3.65
H-ANT ADP-ribosylation factor 1 Arf1 11 TWC 16.31 27.94 3.23 17.06 23.97 3.73
H-ANT Fibroblast growth factor (acidic) intracellular-binding
protein
Fibp 19 CSD 17.16 27.91 3.50 2.78 2.07 6.41
H-ANT HECT domain containing 1 Hectd1 12 UNK 17.06 27.91 3.47 2.91 4.48 7.42
H-ANT ATP synthase, Hþ transporting, mitochondrial
F1 complex, gamma polypeptide 1
Atp5c1 2 TWC 17.32 27.89 3.44 16.95 18.03 4.58
H-ANT Nuclear RNA export factor 1 homolog (S. cerevisiae) Nxf1 19 TWC 17.27 27.89 3.55 5.61 3.63 7.63
L-ANT B-cell receptor-associated protein 29 Bcap29 12 TWC 2.28 0.85 19.94 22.83 13.98 4.32
L-ANT Neighbor of Punc E11 Nope 9 TIC 2.22 0.85 20.15 7.42 5.80 4.95
L-ANT v-rel reticuloendotheliosis viral oncogene
homolog A (avian)
Rela 19 TRA 1.83 0.85 17.88 23.73 16.84 4.03
L-ANT Fat-speciﬁc gene 27 Fsp27 6 CSD 2.41 0.87 14.43 19.92 10.81 4.21
L-ANT Ligand of numb-protein X 2 Lnx2 5 SIG 2.75 0.87 15.86 4.29 6.59 3.34
L-ANT ras homolog gene family, member H Arhh 5 SIG 2.20 0.87 17.74 2.54 0.95 13.59
L-ANT CpG-binding protein Cgbp-pend 18 TRA 1.85 0.90 23.68 18.51 19.39 4.05
L-ANT Hydroxyacid oxidase 1, liver Hao1 2 ENE 2.30 0.90 18.96 10.17 5.72 5.72
L-ANT miRNA containing gene Mirg 12 UNK 2.04 0.90 24.36 9.24 5.88 4.74
L-ANT Sphingosine-1-phosphate phosphatase 1 Sgpp1 12 ENE 2.25 0.90 19.33 12.45 10.54 4.69
H-IND Anterior gradient 2 (Xenopus laevis) Agr2 12 UNK 1.03 1.51 26.11 6.99 3.20 7.73
H-IND Argininosuccinate lyase Asl 5 ENE 1.67 0.93 25.85 7.36 4.98 6.44
H-IND Cytotoxic T-lymphocyte-associated protein 2 beta Ctla2b 12 JAE 0.90 1.67 25.85 19.12 14.22 3.55
H-IND ATP-binding cassette, sub-family G (WHITE), member 4 Abcg4 9 TIC 1.14 1.38 25.74 6.44 10.20 5.03
H-IND Sorting nexin 10 Snx10 6 TWC 1.01 1.67 25.72 16.98 23.83 4.10
H-IND myc-induced nuclear antigen Mina 16 CSD 1.75 1.03 25.48 20.34 10.91 4.16
H-IND Acetyl-coenzyme A acyltransferase 2
(mitochondrial 3-oxoacyl-coenzyme A thiolase
Acaa2 18 ENE 1.35 1.30 25.32 17.64 23.57 3.76
H-IND Ena-vasodilator stimulated phosphoprotein Evl 12 SIG 1.01 1.77 25.32 8.63 4.45 4.79
H-IND Solute carrier family 25 (mitochondrial carrier;
ornithine transporter), member 15
Slc25a15 8 TWC 1.59 1.11 25.19 11.10 6.25 5.40
H-IND AE-binding protein 2 Aebp2 6 TRA 1.80 0.95 24.97 1.85 4.82 16.45
L-IND Acidic (leucine-rich) nuclear phosphoprotein
32 family, member E
Anp32e 3 UNK 26.30 13.22 2.83 4.79 1.48 16.31
L-IND Fatty acid amide hydrolase Faah 4 ENE 27.20 14.38 2.83 18.46 9.90 4.56
L-IND Meiotic recombination 11 homolog A (S. cerevisiae) Mre11a 9 ENE 26.24 13.11 2.83 24.02 16.98 5.48
L-IND BCL2-associated athanogene 4 Bag4 8 CSD 25.98 12.95 2.89 15.76 8.18 5.08
L-IND KDEL containing protein 1 Kdel1 1 TRA 26.22 13.19 2.89 24.02 16.98 3.34
(Continued)
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conﬁrmed by qRT-PCR; Matejuk et al., 2003). As illustrated in Table 8,
when common hits were compared between data sets, only 2 of 40 genes
(granulin and mevalonate diphospho decarboxylase) showed opposite
regulation. Even though magnitudes of expression changes varied
between these studies, thisqualitative OVL is remarkable, given reports of
poor correlations between results provided by different microarray
platforms even for the same extracts (e.g., Knudtson et al., 2002).
Connexin43 is a key gene of the SC transcriptome
The remarkable OVL between the regulomes of AT-EAE SC and Cx43 null
brainindicates that in pathological conditions in which Cx43 isregulated a
subset of the altered transcriptome may be attributable to the alteration in
Cx43.Thisﬁndingprovidesadditionalsupport forthehypothesis thatCx43
is a node of gene expression regulation, where its expression is closely
tied to that of many other genes (Iacobas et al., 2007a; Iacobas et al.,
2007b; Spray and Iacobas, 2007). Although mechanisms responsible for
the regulation of other genes by Cx43 expression remain to be completely
understood, they likely include regulation of signal molecule exchange
between coupled cells and binding to Cx43 cytoplasmic domains of
molecules with TRA factor activity (see Kardami et al., 2007).
Gene cohorts were perturbed but not regulated
Cohort analysis of quantiﬁed genes has the advantage of providing both
manageable and statistically signiﬁcant ontological information. The
expression analysis of gene cohorts is signiﬁcantly more accurate than
that of individual genes due to averaging of technical noise in expression
levels of individual genes. In addition, it provides a measure of tendency
toward particular patterns of expression. Although we found that no gene
cohort was signiﬁcantly regulated in AT-EAE SC with respect to control
(due to a rough balance between up- and down-regulation of individual
genes), all cohorts were signiﬁcantly perturbed, meaning that the disease
signiﬁcantly altered the proportions of transcript abundances within each
cohort. Presumably, these ‘‘stoichiometric’’ perturbations contribute to
phenotypic alterations that lead to neurological impairment in AT-EAE,
including the inﬂammation, demyelination, axonal damage, and cell death
that are associated with inﬁltration of myelin-speciﬁc inﬂammatory Th1
CD4
þ T-cells and, subsequently, activated monocytes into the CNS
(Ercolini and Miller, 2006). Interestingly, the highest perturbation was that
of JAE genes and chromosome 17 due to the up-regulation of all nine
histocompatibility 2 genes involved in immune defense response that
were quantiﬁed (H2-Aa, H2-Ab1, H2-Eb1, H2-Dma, H2-Bf, H2-D1, H2-K,
H2-L, H2-Q7), consistent with the inﬂammatory nature of the disease.
Remarkably, mouse chromosome 17 has the largest homology with
human chromosome 6p21, the locus containing the major histocompat-
ibility complex known to inﬂuence susceptibility to MS (Yeo et al., 2007).
AT-EAE SC has a loose control of gene expression
Since AT-EAE represents a massive immunological response resulting in
gross tissue changes, we examined whether this condition altered the
overall inter-animal gene expression variability as compared to healthy
mice, expecting that AT-EAE mice would have greater variability due to
differences in disease status or in immune attack. Indeed, although for
44.3% of the studied genes the TRA variability decreased, the overall REV
value increased from 42.5% in the control mice to 49.7% in the AT-EAE
mice, indicating a signiﬁcant (p < 0.0001) loss of the overall TRA control
in the diseased mice. In addition, the sets of REV values in the two
conditions were independent (r < 10
 23) suggesting that multiple
mechanisms may contribute to alter the TRA control stringency of
individual genes.
Among the most stably expressed genes in control SC whose
expression was not affected by AT-EAE was cadherin 2 (Cdh2), which is
required for regulating presynaptic function at glutamatergic synapses
(Jungling et al., 2006). In contrast, interleukin-1 receptor-associated
kinase 1 (Irak1), critical for the induction of EAE as well as for the
activation and expansion of autoreactive T-cells (Deng et al., 2003), was
very stably expressed in control but became very unstably expressed in
AT-EAE, in line withthe dynamicnature ofthe inﬂammatory process in the
disease.
AT-EAE remodels the expression coordination network in SC
The coordination analysis revealed complex interlinkages of gene
expression in both control and AT-EAE SC and that the pathology not only
alters expression of individual genes but also perturbs functional
pathways and rearranges transcriptomic interlinkages However, AT-EAE
did not change signiﬁcantly the average extents of the synergomes,
antagomes,andexclusomes,incontradictionwithwhatwehaveobserved
in Cx43 null brain were the expressome sizes diminished by more than
20% with respect to the wildtype brain (Iacobas et al., 2007a).
Adam10, the disintegrin and metalloprotease that modulates the cell
adhesion role of Pcdh gamma (Reiss et al., 2006) displayed the largest
synergome (28.0%), while spastic paraplegia 7 homolog (Spg7), encoding
a protein involved in anterograde axon cargo transport (Ferreirinha et al.,
2004), had the largest antagome (28%). Remarkably, peripheral myelin
protein (Pmp22) was found to be the most coordinately expressed gene
involved in myelination (43.2%), while neutral sphingomyelinase
activation-associatedfactor(Nsmaf)wasfoundtobetheleastcoordinated
(5.0%). The very large expressome of Pmp22 is consistent with its role in
mediating the interaction of Schwann cells with the extracellular
environment (Amici et al., 2006; Amici et al., 2007; Berger et al., 2006)
and the consequences of its misexpression in generating a family of
hereditary peripheral neuropathies (Amici et al., 2007; Sereda and Nave,
2006).
Among the genes responsible for the immune response, interferon-
induced transmembrane protein 3 (Iﬁtm3), involved in the negative
Table 4. (Continued).
Type Name Symbol CHR FUNC SYN-C ANT-C IND-C SYN-E ANT-E IND-E
L-IND Nuclear fragile X mental retardation protein
interacting protein
Nuﬁp1 14 TWC 24.55 11.57 2.89 13.16 6.81 5.22
L-IND T-box 2 Tbx2 11 TRA 26.01 12.71 2.89 19.23 20.37 3.42
L-IND Disrupted in bipolar disorder 1 homolog (human) Dibd1 9 TRA 27.09 14.27 2.91 9.19 5.27 5.61
L-IND Phosphatidylglycerophosphate synthase 1 Pgs1-pend 11 UNK 14.19 27.12 2.91 1.11 2.01 7.71
L-IND Solute carrier family 4, sodium bicarbonate
cotransporter, member 7
Slc4a7 14 TIC 26.22 13.29 2.91 5.01 2.38 10.67
CHR, chromosome location; FUNC, primary function performed by the encoded protein.
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expressome (44.4%) and Fc receptor IgG low afﬁnity III (Fcgr3) the
smallest (2.5%). Iﬁtm3 also displayed the largest antagome (27.8%),
while histocompatibility 2 class II antigen E beta (H2-Eb1), involved in
antigen processing via MHC class II (Alfonso et al., 2001), had the largest
synergome (27.5%). Immediate early response 3 (Ier3) appeared to have
the largest exclusome (11.2%). Complex gene–gene interactions within
the inﬂammatory pathway have also been reported by other groups. For
example, Motsinger et al., 2007 explored 51 single nucleotide
polymorphisms (SNPs) in 36 candidate genes within the inﬂammatory
pathway, ﬁnding that multi-locus models successfully predicted MS
disease risk with high accuracy.
The bimodaldistributions ofthe expressome sizes of SC in bothcontrol
and disease (Figure 3B), was more prominent than that found in the brain
Table 5. The extent of the synergomes (SYN), antagomes (ANT), expresomes (EXP ¼ SYN þ ANT), and exclusomes (EXC) of the immune
response genes in the control spinal cord.
Name Symbol SYN ANT EXP EXC
B-cell receptor-associated protein 31 Bcap31 17.46 27.23 44.69 1.91
Interferon-induced transmembrane protein 3 Iﬁtm3 16.58 27.79 44.37 1.64
Histocompatibility 2, class II antigen E beta H2-Eb1 27.50 15.84 43.34 1.56
Chemokine-like factor super family 3 Cklfsf3 27.34 15.52 42.86 1.48
B-lymphoma Mo-MLV insertion region 1 Bmi1 16.45 25.72 42.17 1.70
Histocompatibility 13 H13 24.64 17.35 41.99 1.93
CD1d1 antigen Cd1d1 16.13 24.74 40.87 1.64
CD44 antigen Cd44 16.87 21.91 38.78 2.04
Proteosome (prosome, macropain) subunit, beta type
8 (large multifunctional protease 7)
Psmb8 23.34 15.18 38.52 1.85
Cd300D antigen Cd300d 16.50 20.13 36.64 2.04
Chemokine (C–C motif) ligand 22 Ccl22 23.52 10.49 34.01 1.70
Histocompatibility 2, L region H2-L 18.07 14.52 32.58 2.12
B-cell leukemia/lymphoma 2-related protein A1d Bcl2a1d 12.13 20.29 32.42 2.17
Small chemokine (C–C motif) ligand 11 Ccl11 11.87 19.36 31.23 1.59
Interferon regulatory factor 6 Irf6 18.57 9.99 28.56 1.91
Interleukin 2 receptor, gamma chain Il2rg 19.05 8.77 27.81 1.75
Histocompatibility 2, class II, locus DMa H2-DMa 16.72 8.34 25.06 2.01
Proteosome (prosome, macropain) subunit, beta type
9 (large multifunctional protease 2)
Psmb9 16.72 8.08 24.79 2.09
Histocompatibility 2, class II antigen A, alpha H2-Aa 12.37 10.62 22.99 1.85
SAM domain and HD domain, 1 Samhd1 12.13 9.64 21.77 1.83
LPS-responsive beige-like anchor Lrba 14.17 7.02 21.19 2.09
Proteasome (prosome, macropain) 28 subunit, alpha Psme1 9.56 11.15 20.72 1.80
Fc receptor, IgE, high afﬁnity I, gamma polypeptide Fcer1g 9.99 9.30 19.28 2.86
Histocompatibility 2, class II antigen A, beta 1 H2-Ab1 12.40 5.85 18.25 2.12
Complement component 1, q subcomponent, alpha polypeptide C1qa 5.06 12.56 17.62 2.04
Interferon-induced transmembrane protein 3-like Iﬁtm3l 9.83 6.86 16.69 2.52
Interferon-induced transmembrane protein 1 Iﬁtm1 4.03 11.36 15.39 1.83
20-50-oligoadenylate synthetase-like 2 Oasl2 10.70 4.03 14.73 2.52
Chemokine (C–C motif) ligand 9 Ccl9 6.83 5.96 12.79 2.75
ICOS ligand Icosl 6.44 6.15 12.58 2.23
Interferon activated gene 203 Iﬁ203 8.53 3.39 11.92 2.25
Histocompatibility 2, Q region locus 7 H2-Q7 8.03 3.79 11.81 2.28
Tumor necrosis factor, alpha-induced protein 2 Tnfaip2 7.60 3.55 11.15 1.96
Complement component 1, q subcomponent, beta polypeptide C1qb 7.50 2.70 10.20 2.46
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Cd47 5.48 4.56 10.04 2.86
Histocompatibility 2, K1, K region H2-K1 5.93 3.74 9.67 2.12
Chemokine (C motif) ligand 1 Xcl1 5.43 2.15 7.58 3.02
T-cell receptor alpha, variable 22.1 Tcra-V22.1 4.53 2.78 7.31 2.97
SLAM family member 8 Slamf8 4.90 2.04 6.94 3.15
Interleukin 7 receptor Il7r 3.50 1.93 5.43 7.26
Histocompatibility 2, complement component factor B H2-Bf 1.77 3.31 5.09 7.84
IL2-inducible T-cell kinase Itk 3.34 1.72 5.06 4.64
Interferon consensus sequence-binding protein 1 Icsbp1 2.70 2.15 4.85 6.78
Complement component factor h Cfh 2.83 1.93 4.77 6.91
Complement component 3 C3 2.60 2.09 4.69 3.18
Histocompatibility 2, D region locus 1 H2-D1 2.20 1.72 3.92 4.79
Interleukin 1 family, member 6 Il1f6 2.75 1.01 3.76 10.68
Interferon regulatory factor 1 Irf1 2.68 1.09 3.76 8.00
Interleukin 11 receptor, alpha chain 1 Il11ra1 1.14 2.60 3.74 9.17
Guanylate nucleotide-binding protein 2 Gbp2 1.88 1.48 3.36 5.32
Macrophage expressed gene 1 Mpeg1 1.14 1.59 2.73 9.99
Immediate early response 3 Ier3 1.06 1.59 2.65 11.15
Fc receptor, IgG, high afﬁnity I Fcgr3 1.17 1.40 2.57 7.87
T-complex-associated testis expressed 3 Tcte3 1.01 1.40 2.41 12.29
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www.frontiersin.orgTable 6. Examples of genes that preserved (HH and LL) or signiﬁcantly changed (HL and LH) the coordination (SYN þ ANT) degree in AT-EAE
(E) spinal cord as compared to controls (C).
Type Name Symbol CHR FUNC SYN-C ANT-C IND-C SYN-E ANT-E IND-E
HH B-cell receptor-associated protein 31 Bcap31 X TWC 17.45 27.22 3.42 19.25 22.17 3.39
HH E4F transcription factor 1 E4f1 17 TRA 27.04 17.66 3.47 22.46 18.94 3.65
HH Ferrochelatase Fech 18 ENE 27.78 17.27 3.50 21.98 19.23 3.44
HH Fibroblast growth factor receptor 1 Fgfr1 8 CSD 27.28 17.53 3.50 23.73 17.43 3.84
HH Gamma-glutamyl carboxylase Ggcx 6 ENE 27.89 16.79 3.31 22.80 17.61 3.18
HH Golgi apparatus protein 1 Glg1 8 TWC 27.36 17.24 3.47 23.17 18.19 3.26
HH Immediate early response 5 Ier5 1 CSD 17.24 27.44 3.36 18.22 23.33 3.39
HH Mpv17 transgene, kidney disease mutant Mpv17 5 ENE 27.75 16.84 3.31 24.02 17.32 3.55
HH Neural proliferation, differentiation and control gene 1 Npdc1 2 UNK 27.86 17.13 3.47 21.61 18.83 3.55
HH Nuclear cap-binding protein subunit 2 Ncbp2 16 UNK 27.73 17.27 3.55 23.70 18.06 3.36
HH Placental-speciﬁc protein 1 Plac1 X UNK 17.40 27.20 3.50 23.33 18.59 3.20
HH Ring ﬁnger protein 103 Rnf103 6 TRA 27.81 17.11 3.58 24.05 17.88 3.44
HH SEC61, gamma subunit Sec61g 11 TWC 17.40 27.33 3.50 18.06 23.41 3.68
HH Transducin-like enhancer of split 4, E(spl) homolog (Drosophila) Tle4 19 TRA 27.54 17.29 3.58 24.02 17.45 3.10
HH Ubiquitination factor E4B, UFD2 homolog (S. cerevisiae) Ube4b 4 ENE 27.30 17.29 3.44 21.85 19.07 3.23
HL Bromodomain containing 3 Brd3 2 TRA 27.94 16.66 3.39 4.77 2.01 14.14
HL Calcium-binding protein, intestinal Cai 6 SIG 27.75 17.16 3.28 4.32 1.43 11.94
HL Capicua homolog (Drosophila) Cic 7 TWC 16.98 27.73 3.50 0.64 1.93 25.56
HL Drebrin-like Dbnl 11 CYT 17.11 27.81 3.65 2.36 2.36 5.61
HL Ferredoxin reductase Fdxr 11 ENE 27.09 17.61 3.58 1.56 2.30 7.47
HL Fibroblast growth factor (acidic) intracellular-binding protein Fibp 19 CSD 17.16 27.91 3.50 2.78 2.07 6.41
HL FLN29 gene product Fln29-pend 5 UNK 27.91 17.43 3.50 0.87 0.82 14.35
HL HECT domain containing 1 Hectd1 12 UNK 17.06 27.91 3.47 2.91 4.48 7.42
HL Inhibitor of kappaB kinase epsilon Ikbke 1 SIG 27.86 17.13 3.52 1.40 0.79 13.51
HL Myotubularin-related protein 1 Mtmr1 X CYT 27.97 17.19 3.39 5.46 1.48 8.10
HL Phosphatidylinositol-4-phosphate 5-kinase, type II, alpha Pip5k2a 2 ENE 16.90 27.75 3.58 1.69 1.72 17.61
HL Procollagen C-endopeptidase enhancer 2 Pcolce2 9 JAE 17.16 27.65 3.55 3.60 2.38 15.12
HL Protein tyrosine phosphatase, non-receptor type 9 Ptpn9 9 SIG 17.13 28.02 3.42 1.14 3.87 16.58
HL Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 6 ENE 27.81 17.21 3.44 2.89 0.85 9.06
HL von Hippel–Lindau-binding protein 1 Vbp1 X TWC 16.84 27.83 3.20 1.62 2.67 8.61
LH Abhydrolase domain containing 3 Abhd3 18 ENE 0.95 1.93 18.88 17.21 23.86 3.20
LH Acetyl-coenzyme A acyltransferase 2
(mitochondrial 3-oxoacyl-coenzyme A thiolase)
Acaa2 18 ENE 1.35 1.30 25.32 17.64 23.57 3.76
LH ATP synthase, Hþ transporting, mitochondrial
F0 complex, subunit c (subunit 9), isoform 2
Atp5g2 15 TWC 1.22 1.62 19.92 17.29 24.02 3.47
LH Hematopoietically expressed homeobox Hhex 19 TRA 1.24 1.22 19.15 23.65 17.16 3.84
LH Immediate early response 3 Ier3 17 CSD 1.06 1.59 22.75 16.23 23.41 4.21
LH Interleukin-1 receptor-associated kinase 1 Irak1 X SIG 1.38 1.11 19.54 19.31 22.48 3.36
LH Polymerase (DNA directed), beta Polb 8 TRA 1.77 1.11 14.96 23.54 16.26 3.97
LH RAD9 homolog (S. pombe) Rad9 19 CSD 1.88 0.95 21.35 23.15 18.86 3.05
LH Resistin like beta Retnlb 16 UNK 1.69 1.19 16.39 21.74 19.20 3.50
LH Retinol-binding protein 4, plasma Rbp4 19 TWC 1.93 0.98 17.45 23.62 18.30 3.73
LH RME8 protein Rme8-pend 9 UNK 1.59 1.11 22.80 16.92 23.09 3.23
LH Sorting nexin 10 Snx10 6 TWC 1.01 1.67 25.72 16.98 23.83 4.10
LH Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
beta polypeptide
Ywhab 2 TWC 1.48 1.22 12.00 19.17 22.25 3.36
LH UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 4
Galnt4 10 ENE 1.91 1.01 22.67 23.25 18.64 3.39
LH v-rel reticuloendotheliosis viral oncogene
homolog A (avian)
Rela 19 TRA 1.83 0.85 17.88 23.73 16.84 4.03
LL AE-binding protein 2 Aebp2 6 TRA 1.80 0.95 24.97 1.85 4.82 16.45
LL CDC26 subunit of anaphase promoting complex Cdc26-pen 4 CSD 1.80 1.03 12.66 3.81 2.15 13.72
LL COP9 (constitutive photomorphogenic) homolog,
subunit 4 (Arabidopsis thaliana)
Cops4 5 TRA 1.09 1.59 22.62 3.34 2.94 10.62
LL Fc receptor, IgG, low afﬁnity III Fcgr3 1 JAE 1.17 1.40 15.63 2.17 2.44 5.88
LL Glypican 1 Gpc1 1 JAE 1.22 1.32 18.91 2.67 2.54 5.56
LL Hairy/enhancer-of-split related with YRPW motif-like Heyl 4 TRA 1.93 0.93 24.21 0.82 0.74 16.34
LL Leucine-zipper-like transcriptional regulator, 1 Lztr1 16 TRA 1.77 1.14 20.31 2.17 2.44 4.13
LL Msx2 interacting nuclear target protein Mint-pendin 4 UNK 1.62 1.17 21.80 4.63 2.01 14.30
LL NADH dehydrogenase (ubiquinone) Fe-S protein 1 Ndufs1 1 ENE 1.30 1.24 15.52 2.15 1.40 12.50
LL Piwi like homolog 2 (Drosophila) Piwil2 14 CSD 1.30 1.24 24.76 2.73 0.90 6.41
LL Pre-B-cell leukemia transcription factor 3 Pbx3 2 TRA 1.40 1.51 12.05 2.04 1.88 19.33
(Continued)
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genes in terms of coordinations with other genes.
The perspective of ‘‘see-saw’’ partnership
The redundancy provided by similar or opposite coordination proﬁles may
offer the possibility to compensate for functional effects of alteration in
gene expression through regulation of interlinked partners. The striking
similarity or opposition with regard to coordination proﬁle of Pmp22 with
genes such as Pdgfra and Pdgfrl (Figure 5B) may explain why some of the
Pdgf genes have been reported to act individually and/or cooperatively in
spontaneous remyelination (Murtie et al., 2005). A particularly interesting
result ofour study was the ﬁnding of strikingly similar oropposite partners
of Pmp22 in the immune response gene cohort (Cklfsf3 and Iﬁtm3, Figure
LL Solute carrier family 5 (sodium-dependent
vitamin transporter), member 6
Slc5a6 5 TIC 1.11 1.40 16.18 0.50 0.87 18.19
LL TBP-interacting protein Tp120a-pe 10 TRA 1.69 1.24 9.38 2.04 2.41 18.03
LL von Hippel–Lindau syndrome homolog Vhlh 6 TWC 1.17 1.43 16.10 4.58 1.56 15.20
LL WD repeat domain 9 Wdr9 16 TRA 1.24 1.59 10.54 1.59 4.13 9.38
H, high coordination; L, low coordination, ﬁrst symbol in Type column indicating the coordination degree in the C and second one in the E extract; CHR,
chromosome location; FUNC, primary function performed by the encoded protein; SYN, synergistic expression; ANT, antagonistic expression; IND,
independent expression.
Table 6. (Continued).
Type Name Symbol CHR FUNC SYN-C ANT-C IND-C SYN-E ANT-E IND-E
Figure 5. See-saw partners of peripheral myelin protein (Pmp22) in control spinal cord and alteration by AT-EAE. (A and D) Immune response partners.
(B and E) Platelet derived growth factors. (C and F) Calcium signaling genes. The correlation coefﬁcients of the indicated genes with each other gene were plotted
against those of Pmp22 with each other gene. In controls, red color indicates likeness, green neutrality, and blue opposition. The table presents the overlap (OVL)
of the coordination proﬁles in both conditions. Note that the AT-EAE turned the signiﬁcant similarity and opposition of the coordination proﬁles into neutrality.
Cklfsf3, chemokine-like factor super family 3; Iﬁtm3, interferon-induced transmembrane protein 3; Ier3, immediate early response 3; Pdgfra, platelet derived
growth factor receptor, alpha polypeptide; Pdfrl, platelet-derived growth factor, receptor-like; Pdgfc, platelet-derived growth factor, C polypeptide; Itpr1, inositol
1,4,5-triphosphate receptor1;Grinl1a,glutamate receptor, ionotropic, N-methylD-aspartate-like 1A; P2rx3,purinergicreceptorP2X,ligand-gatedionchannel,3.
The overlap scores (OVL) of the Pmp22 in the two conditions were:
Partner  Cklfsf3 Ifitm3 Ier3  Pdgfra Pdfrl  Pdgfc  Itpr1  Grinl1a P2rx3 
−0.86  −95.59  92.30  3.94  −81.12  93.23  −4.56  −93.57  98.51  Control 
0.50  37.86  −6.09  −15.15  2.72  −12.17  16.34  21.44  15.54  AT-EAE 
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(Itpr1) and glutamate receptor ionotropic N-methyl D-aspartate-like 1A
(Grinl1a)) (Figure 5C). Itpr1 is responsible for calcium mobilization from
the endoplasmic reticulum calcium stores (Iacobas et al., 2006b), while
Grinl1a allows calcium ions from the extracellular space to diffuse into the
cell when activated by glutamate. The existence of these ‘‘see-saw’’
partnersofmyelinationgenessuggeststhepossibilityofcorrecting myelin
defects through stimulating or inhibiting genes responsible for calcium
Table 7. The most like (OVL > 90) and opposite (OVL <  90) see-saw partners among genes involved in myelination (MYE), calcium
signaling (CAS), and immune response (IRS) in spinal cord of adult control female mice.
Pair OVL Pair OVL Symbol Name
H2-DMa:Psmb9 99.45 Scd2:Plcl2  99.84 Bcap31 B-cell receptor-associated protein 31
Pdgfra:Pdia4 99.17 H2-Eb1:Iﬁtm3  97.48 Bcl2a1b B-cell leukemia/lymphoma 2-related protein A1b
Pmp22:Cmtm3 98.52 Pmp22:Grinl1a  95.59 Bmi1 B lymphoma Mo-MLV insertion region 1
Plp:Fyn 97.60 Cd1d1:H13  94.84 C1qb Complement component 1, q subcomponent,
beta polypeptide
Bmi1:Cd1d1 97.34 Pdgfra:Grinl1a  94.70 Cab39 Calcium-binding protein 39
Cd44:Cd300d 97.14 Iﬁtm1:Oasl2  94.44 Capns1 Calpain, small subunit 1
H2-Ab1:Lrba 96.84 Mal:Tuba8  94.25 Ccl11 Small chemokine (C–C motif) ligand 11
Pdgfrl:Mal 96.22 Cmtm3:Iﬁtm3  94.20 Cd1d1 CD1d1 antigen
Pdgfrb:Cab39 96.19 Bmi1:H13  93.79 Cd300d Cd300D antigen
Pdgfrb:H2-Aa 95.44 Pmp22:Iﬁtm3  93.57 Cd44 CD44 antigen
Cmtm3:H2:Eb1 95.10 C1qb:H2-Ab1  93.47 Cherp Calcium homeostasis endoplasmic reticulum protein
Bcap31:Iﬁtm3 94.93 C1qb:Lrba  93.42 Cmtm3 CKLF-like MARVEL transmembrane domain
containing 3
Il2rg:Psmb9 94.78 Bcap31:H2-Eb1  92.57 Fyn Fyn proto-oncogene
Pmp22:S100a6 94.67 Pdgfra:Plcd1  92.04 Grinl1a Glutamate receptor, ionotropic, N-methyl
D-aspartate-like 1A
H2-Dma:Il2rg 94.44 Cd44:H13  92.01 H13 Histocompatibility 13
Pmp22:H2:Eb1 94.01 Bcl2a1b:Irf6  91.93 H2-Aa Histocompatibility 2, class II antigen A, alpha
Pmp22:Pdia4 93.90 Pdgfrl:S100g  91.91 H2-Ab1 Histocompatibility 2, class II antigen A, beta 1
Scd2:Snx9 93.85 Ccl11:Psmb8  91.89 H2-DMa Histocompatibility 2, class II, locus DMa
Mpz:Hmgcr 93.82 Pdgfrl:Tuba8  91.79 H2-Eb1 Histocompatibility 2, class II antigen E beta
Pdgfrb:H2-L 93.70 Scd2:Tuba8  91.78 H2-K1 Histocompatibility 2, K1, K region
Mal:Qk 93.49 Pmp22:Hspb1  91.34 H2-L Histocompatibility 2, L region
Pmp22:Capn3 93.37 Pdgfra:Hspb1  90.96 H2-Q7 Histocompatibility 2, Q region locus 7
Irf6:Lrba 93.34 Bcap31:Psmb8  90.51 Hmgcr 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
Pdgfrl:Qk 93.28 Bcap31:Cmtm3  90.23 Hspb1 Heat shock protein 1
Pmp22:Pdgfra 93.23 Bcap31:Pmp22  90.16 Iﬁtm1 Interferon-induced transmembrane protein 1
Pdgfra:S100a6 93.19 H13:Cd300d  90.02 Iﬁtm3 Interferon-induced transmembrane protein 3
Pdgfra:Itpr1 92.66 Iﬁtm3l Interferon-induced transmembrane protein 3-like
Pdgfrb:Camk2g 92.49 Il2rg Interleukin 2 receptor, gamma chain
Mal:Snx9 92.39 Irf6 Interferon regulatory factor 6
Pmp22:Itpr1 92.30 Itpr1 Inositol 1,4,5-triphosphate receptor 1
Pdgfrb:Fyn 92.06 Lrba LPS-responsive beige-like anchor
Pmp22:Capns1 91.58 Mal Myelin and lymphocyte protein, T-cell
differentiation protein
Pdgfra:Capns1 91.54 Mpz Myelin protein zero
Pmp22:Pde4a 91.54 Oasl2 20-50-Oligoadenylate synthetase-like 2
Pdgfra:Plcg2 91.43 Pdgfra Platelet-derived growth factor receptor,
alpha polypeptide
H2:Ab1:Irf6 91.32 Pdgfrb Platelet-derived growth factor receptor,
beta polypeptide
Pdgfra:Capn3 91.31 Pdgfrl Platelet-derived growth factor receptor-like
Plp:Cab39 90.92 Pdia4 Protein disulﬁde isomerase-associated 4
Pdgfrl:Snx9 90.90 Plcd1 Phospholipase C, delta 1
Scd2:Cherp 90.66 Plcl2 Phospholipase C-like 2
H2-Aa:H2-L 90.47 Plp Proteolipid protein (myelin)
Pdgfrl:Cd44 90.45 Pmp22 Peripheral myelin protein
Pdgfrl:S100a11 90.35 Psmb8 Proteosome (prosome, macropain) subunit, beta type
8 (large multifunctional protease 7)
Bcl2a1b:Cd1d1 90.33 Psmb9 Proteosome (prosome, macropain) subunit, beta type
9 (large multifunctional protease 2)
Bcl2a1b:Bmi1 90.32 Qk Quaking
Plp-H2-Aa 90.30 S100a11 S100 calcium-binding protein A11 (calizzarin)
H2:K1:H2:Q7 90.16 S100a6 S100 calcium-binding protein A6 (calcyclin)
H2-Ab1-Tnfaip2 90.06 S100g S100 calcium-binding protein G
Pdgfrb:Plp 90.05 Scd2 Stearoyl-coenzyme A desaturase 2
Snx9 Sorting nexin 9
Tnfaip2 Tumor necrosis factor, alpha-induced protein 2
Tuba8 Tubulin, alpha 8
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interlinkage with thousands of genes. These relations between the
coordination proﬁles can be substantially altered in pathological
conditions as presented in Figures 5D–5F. These ﬁndings of network
alterations add a novel concept to expression analysis, in which gene
expression proﬁles can be considered not only by whether expression of
genes in a similar functional pathway are affected, but also with regard to
how their linkage to one another is altered in a disease state.
We have previously reported (Brand-Schieber et al., 2005) that the
geneencodingthegapjunctionprotein Cx43,themostabundantconnexin
expressedinastrocytes,wasamongthedown-regulatedgenesinAT-EAE,
a result recently conﬁrmed in a guinea pig model of EAE (Roscoe et al.,
2007). We concluded that in addition to damage of myelinating glia,
altered astrocyte connectivity is a prominent feature of inﬂammatory
demyelination. In order to test the hypothesis that coordinated expression
with Cx43 might account for some of the observed altered patterns of
gene expression, we have compared the coordination proﬁle of Gja1 to
those of the immune response and myelination genes quantiﬁed in this
experiment. Thus, the coordination proﬁle of Gja1 had a remarkable
likeness with those of: histocompatibility 2 Q region locus 7 (H2-Q7,
OVL ¼ 87.4%), Psmb9 (OVL ¼ 84.8%), H2-DMa (OVL ¼ 84.5%),
interleukin 2 receptor gamma chain (Il2rg, OVL ¼ 83.6%), myelin protein
zero (Mpz, OVL ¼ 82.4%), complement component 1 q subcomponent
beta polypeptide (C1qb, OVL ¼ 81.6%), and proteolipid protein (myelin)
(Plp, OVL ¼ 75.5%). These associations may suggest that the
consequences of altered Cx43 expression in damaged SC, evoked by
endogenous mechanisms after traumatic SCI (Theriault etal., 1997)might
be compensated by overexpression of these other genes. In this regard,
we particularly highlight the myelination genes Mpz and Plp because of
the prevalence of white matter disturbance in oculodentodigital dysplasia
syndrome (Loddenkemper et al., 2002), which is caused by dysfunctional
Cx43mutations(Shibayamaetal.,2005).Asacorollaryofthishypothesis,
Table8.Common hits for EAE spinal cord in this study and that by Matejuk et al., (13) obtained through Affymetrix (Affy) and qRT-PCR (QPCR)
techniques.
Name Symbol cDNA p-Value Affy p-Value QPCR
Beta-2 microglobulin B2m 5.59 0.001 10.8 0.010
Cathepsin C Ctsc 4.14 0.001 21.1 0.000 12.0
Cathepsin S Ctss 14.23 0.000 8.3 0.000
Cathepsin Z Ctsz 5.93 0.000 8.2 0.000
CCAAT/enhancer-binding protein (C/EBP), beta Cebpb 1.32 0.119 4.6 0.010
CD44 antigen Cd44 3.24 0.000 6.2 0.020
CD53 antigen Cd53 1.54 0.404 10.9 0.020
Ceruloplasmin Cp 4.33 0.012 4.6 0.010
Complement component 1, q subcomponent, alpha polypeptide C1qa 10.03 0.000 12.2 0.000
Complement component 1, q subcomponent, beta polypeptide C1qb 8.45 0.000 9.9 0.000
Complement component 3 C3 4.33 0.005 11.4 0.000 8.0
Cysteine-rich protein 1 (intestinal) Crip1 2.39 0.001 8.8 0.030
EGF-like module containing, mucin-like, hormone
receptor-like sequence
Emr1 2.85 0.001 6.3 0.010
Fc receptor, IgG, high afﬁnity I Fcgr1 1.20 0.388 5.6 0.010 5.0
Granulin Grn  2.47 0.003 4.1 0.000
GTP-binding protein 4 Gtpbp4 2.01 0.004 135.8 0.000
Histocompatibility 2, class II antigen A, alpha H2-Aa 26.37 0.000 424.2 0.000 124.6
Histocompatibility 2, class II antigen A, beta 1 H2-Ab1 6.67 0.000 76.0 0.000
Histocompatibility 2, class II antigen E beta H2-Eb1 1.78 0.042 66.1 0.000
Histocompatibility 2, D region locus 1 H2-D1 5.30 0.001 15.8 0.000
Histocompatibility 2, K region H2-K 6.33 0.000 14.4 0.000
Histocompatibility 2, Q region locus 7 H2-Q7 2.44 0.004 19.7 0.000
Ia-associated invariant chain Ii 1.76 0.023 81.1 0.000
Inositol polyphosphate-5-phosphatase B Inpp5b 2.74 0.000 15.0 0.000
Interferon activated gene 203 Iﬁ203 2.79 0.001 4.6 0.020
Interferon consensus sequence-binding protein 1 Icsbp1 3.01 0.000 6.8 0.000
Interferon regulatory factor 1 Irf1 3.04 0.000 10.3 0.000
Lymphocyte speciﬁc 1 Lsp1 1.86 0.022 9.2 0.000
Lysosomal-associated protein transmembrane 5 Laptm5 5.49 0.001 5.7 0.000
Mevalonate (diphospho) decarboxylase Mvd 1.76 0.001  5.4 0.000
mutS homolog 3 (E. coli) Msh3 2.11 0.001 5.1 0.010
Proteasome (prosome, macropain) 28 subunit, alpha Psme1 2.27 0.003 6.3 0.000
SAM domain and HD domain, 1 Samhd1 3.04 0.000 6.8 0.030
Signal transducer and activator of transcription 1 Stat1 6.09 0.000 15.2 0.010 8.0
Signal transducer and activator of transcription 6 Stat6 4.15 0.000 15.8 0.000
Suppressor of cytokine signaling 3 Socs3 1.43 0.017 26.3 0.030
T-cell receptor alpha, variable 22.1 Tcra-V22.1 3.51 0.000 6.0 0.030
Tumor necrosis factor, alpha-induced protein 2 Tnfaip2 3.53 0.000 5.0 0.020
TYRO protein tyrosine kinase-binding protein Tyrobp 2.80 0.000 7.9 0.000
Vesicle-associated membrane protein 8 Vamp8 3.21 0.001 5.8 0.000
Note that all 40 but 2 (enhanced) genes were found to be regulated in the same sense by both cDNA microarray and Affymetrix studies; exceptions are
given in bold. The fold changes obtained by the two platforms was very similar in the case of Laptm5 (98%), Cp (97%), C1qb (92%) andC1qa (90%). Five
common hits were also conﬁrmed by Matejuk et al., 2003 through qRT-PCR.
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increasedCx43expressioninSC.Sucharesulthasbeenrecentlyreported
as a consequence of treatment with two drugs in a guinea pig model of
EAE (Roscoe et al., 2007).
CONCLUSION
We found that AT-EAE had a strong impact on the transcriptomic
organization of the SC, perturbing most of the functional pathways,
relaxing the TRA control, and altering the expression coordination of
numerous genes, including those involved in myelination, immune
response, and calcium signaling. In addition, identiﬁcation of what we
termed ‘‘see-saw’’ partners may provide alternative therapeutic targets
for speciﬁc gene-related diseases.
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